AwesomeCapital
Search This Blog
Monday, February 23, 2026
Gossamer Bio's seralutinib fails to meet primary endpoint threshold in Phase 3
PROSERA PAH trial
Company plans to engage in discussions with the FDA following Phase 3 PROSERA topline results in PAH.
https://finviz.com/quote.ashx?t=GOSS&p=d
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.